Clinical significance of hepatitis B virus associated polymerized human serum albumin receptor (HBV-pAR) activity and anti-par antibody in hepatitis B patients treated with interferon

Hiroshi Ikeda, Yoshiaki Iwasaki, Koichi Takaguchi, Kazuhiro Nouso, Takao Tsuji, Kazuharu Matsuura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the activity of the hepatitis B virus (HBV) associated polymerized human serum albumin receptor (HBV-pAR) and the antibody to HBV-pAR (anti-pAR) in the sera from 14 patients of chronic hepatitis B treated with interferon (IFN) by enzyme-linked immunosorbent assay (ELISA). Seroconversion (SC) of HBeAg was observed in 4 cases at the end of the IFN therapy (treatment), and in 4 cases 6 months after treatment. These cases as above had low HBV-pAR activities before treatment or rapidly decreasing HBV-pAR activities during the treatment. In cases whose HBV-pAR activities decreased minimally during the treatment in spite of the temporal disappearance of HBeAg after the treatment, it reappeared with the exacerbation of S-GPT. On the other hand, S-GPT remained in normal range in the cases with low HBV-pAR levels and positive anti-pAR antibody at the time of SC. These results indicate that HBV-pAR activity and anti-pAR antibody might be more useful markers for determing the outcome of hepatitis B patients treated with IFN.

Original languageEnglish
Pages (from-to)665-669
Number of pages5
JournalJapanese Journal of Clinical Immunology
Volume11
Issue number6
DOIs
Publication statusPublished - 1988

Fingerprint

Albumin Receptors
Hepatitis B
Hepatitis B virus
Serum Albumin
Interferons
Anti-Idiotypic Antibodies
Hepatitis B e Antigens
Antibodies
Therapeutics
Hepatitis B Antibodies
polyalbumin
Chronic Hepatitis B
Reference Values
Enzyme-Linked Immunosorbent Assay

Keywords

  • anti-pAR
  • chronic hepatitis B
  • HBV-pAR
  • interferon

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Clinical significance of hepatitis B virus associated polymerized human serum albumin receptor (HBV-pAR) activity and anti-par antibody in hepatitis B patients treated with interferon. / Ikeda, Hiroshi; Iwasaki, Yoshiaki; Takaguchi, Koichi; Nouso, Kazuhiro; Tsuji, Takao; Matsuura, Kazuharu.

In: Japanese Journal of Clinical Immunology, Vol. 11, No. 6, 1988, p. 665-669.

Research output: Contribution to journalArticle

@article{2e98e161099748a6aff8922f68c0a4c4,
title = "Clinical significance of hepatitis B virus associated polymerized human serum albumin receptor (HBV-pAR) activity and anti-par antibody in hepatitis B patients treated with interferon",
abstract = "We examined the activity of the hepatitis B virus (HBV) associated polymerized human serum albumin receptor (HBV-pAR) and the antibody to HBV-pAR (anti-pAR) in the sera from 14 patients of chronic hepatitis B treated with interferon (IFN) by enzyme-linked immunosorbent assay (ELISA). Seroconversion (SC) of HBeAg was observed in 4 cases at the end of the IFN therapy (treatment), and in 4 cases 6 months after treatment. These cases as above had low HBV-pAR activities before treatment or rapidly decreasing HBV-pAR activities during the treatment. In cases whose HBV-pAR activities decreased minimally during the treatment in spite of the temporal disappearance of HBeAg after the treatment, it reappeared with the exacerbation of S-GPT. On the other hand, S-GPT remained in normal range in the cases with low HBV-pAR levels and positive anti-pAR antibody at the time of SC. These results indicate that HBV-pAR activity and anti-pAR antibody might be more useful markers for determing the outcome of hepatitis B patients treated with IFN.",
keywords = "anti-pAR, chronic hepatitis B, HBV-pAR, interferon",
author = "Hiroshi Ikeda and Yoshiaki Iwasaki and Koichi Takaguchi and Kazuhiro Nouso and Takao Tsuji and Kazuharu Matsuura",
year = "1988",
doi = "10.2177/jsci.11.665",
language = "English",
volume = "11",
pages = "665--669",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Clinical significance of hepatitis B virus associated polymerized human serum albumin receptor (HBV-pAR) activity and anti-par antibody in hepatitis B patients treated with interferon

AU - Ikeda, Hiroshi

AU - Iwasaki, Yoshiaki

AU - Takaguchi, Koichi

AU - Nouso, Kazuhiro

AU - Tsuji, Takao

AU - Matsuura, Kazuharu

PY - 1988

Y1 - 1988

N2 - We examined the activity of the hepatitis B virus (HBV) associated polymerized human serum albumin receptor (HBV-pAR) and the antibody to HBV-pAR (anti-pAR) in the sera from 14 patients of chronic hepatitis B treated with interferon (IFN) by enzyme-linked immunosorbent assay (ELISA). Seroconversion (SC) of HBeAg was observed in 4 cases at the end of the IFN therapy (treatment), and in 4 cases 6 months after treatment. These cases as above had low HBV-pAR activities before treatment or rapidly decreasing HBV-pAR activities during the treatment. In cases whose HBV-pAR activities decreased minimally during the treatment in spite of the temporal disappearance of HBeAg after the treatment, it reappeared with the exacerbation of S-GPT. On the other hand, S-GPT remained in normal range in the cases with low HBV-pAR levels and positive anti-pAR antibody at the time of SC. These results indicate that HBV-pAR activity and anti-pAR antibody might be more useful markers for determing the outcome of hepatitis B patients treated with IFN.

AB - We examined the activity of the hepatitis B virus (HBV) associated polymerized human serum albumin receptor (HBV-pAR) and the antibody to HBV-pAR (anti-pAR) in the sera from 14 patients of chronic hepatitis B treated with interferon (IFN) by enzyme-linked immunosorbent assay (ELISA). Seroconversion (SC) of HBeAg was observed in 4 cases at the end of the IFN therapy (treatment), and in 4 cases 6 months after treatment. These cases as above had low HBV-pAR activities before treatment or rapidly decreasing HBV-pAR activities during the treatment. In cases whose HBV-pAR activities decreased minimally during the treatment in spite of the temporal disappearance of HBeAg after the treatment, it reappeared with the exacerbation of S-GPT. On the other hand, S-GPT remained in normal range in the cases with low HBV-pAR levels and positive anti-pAR antibody at the time of SC. These results indicate that HBV-pAR activity and anti-pAR antibody might be more useful markers for determing the outcome of hepatitis B patients treated with IFN.

KW - anti-pAR

KW - chronic hepatitis B

KW - HBV-pAR

KW - interferon

UR - http://www.scopus.com/inward/record.url?scp=85008550474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008550474&partnerID=8YFLogxK

U2 - 10.2177/jsci.11.665

DO - 10.2177/jsci.11.665

M3 - Article

AN - SCOPUS:85008550474

VL - 11

SP - 665

EP - 669

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 6

ER -